• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds
CMECNE

Lancet Commission: Over a Third of Dementia Cases May be Preventable

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Relate why dementia is projected to be a global health crisis over the upcoming decades
2. List the modifiable risk factors for dementia

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

BACKGROUND AND PURPOSE:

  • Due to an aging population, approximately 50 million people worldwide have dementia, projected to increase to 75 million by 2030 and to 132 million by 2050
  • Symptoms occur late in life but pathology begins early
  • Delay in onset of 1 year could prevent more than 9 million cases of dementia by 2050
    • Delay in onset by 5 years could reduce worldwide prevalence by 50%
  • Livingston et al., under the auspices of The Lancet Commission (Lancet, 2017) investigated the most current evidence regarding diagnosis and treatment of dementia and cognitive impairment
    • As part of this comprehensive review, the Lancet Commission also assessed the evidence related to the impact of modifiable risk factors on dementia, including risk reducing interventions

METHODS:

  • The authors reviewed guidelines and literature to assess modifiable risk factors and interventions
  • ‘All cause’ dementia was used rather than cause-specific dementia because more data was available
  • International studies were included so that results could be more generalizable
  • The authors focused on estimating the ‘Population Attributable Fraction’ (PAF), which is the percentage reduction in new cases over a given time if a particular risk factor is eliminated

RESULTS:

The Lancet Commission identified the following modifiable risk factors for dementia (PAF scores are weighted to provide the unique, relative contribution of each risk factor to the overall PAF):

  • Age < 18 years
    • Education no greater than primary school (PAF=7.5%): relative risk 1.6 (95% CI 1.26-2.01)
  • Age 45-65 years
    • Hypertension (PAF=2.0%): relative risk 1.6 (95% CI 1.16-2.24)
    • Obesity (PAF=0.8%): relative risk 1.6 (95% CI 1.34-1.92)
    • Hearing loss (PAF=9.1%): relative risk 1.9 (95% CI 1.38-2.73)
  • Age > 65 years
    • Smoking (PAF=5.5%): relative risk 1.6 (95% CI 1.15-2.20)
    • Depression (PAF=4.0%): relative risk 1.9 (95% CI 1.55-2.33)
    • Physical inactivity (PAF=2.6%): relative risk 1.4 (95% CI 1.16-1.67)
    • Social isolation (PAF=5.9%): relative risk 1.6 (95% CI 1.32-1.85)
    • Diabetes (PAF=1.2%): relative risk 1.5 (95% CI 1.33-1.79)

KEY POINTS:

Risk Factor Prevention

  • An unexpected decline in dementia has been reported in the US, UK, Canada, Sweden and Netherlands but increased in China and Japan while stable in Nigeria
    • US reported decreased age-specific prevalence was associated with an increase in education
    • While certain lifestyle factors may be improving, concern remains around increasing mid-life rates of obesity
  • Age remains an unmodifiable factor, with 80% of dementias occurring in individuals ≥ 75 years
  • Concept of ‘resilience’ and ‘cognitive reserve’: more brain reserve can tolerate more neuropathology
    • Reserve related to brain anatomical substrate or adaptability of cognition
    • In theory, less reserve leads to earlier onset dementia
      • May explain benefit of education/learning, exercise, blood pressure control
  • Hearing loss: No studies available as to whether hearing aids may delay dementia
  • Physical Activity: Observational studies demonstrate that exercise has a protective effect against cognitive decline, dementia and Alzheimer’s disease
    • RCTs are conflicting regarding effects and type of physical activity
    • Multiple benefits in older people including improved balance, mood, reduced mortality and improved function
  • Validated large scale dementia prevention programs are not yet available
    • Research into multimodal strategies is ongoing

Interventions to Prevent Dementia

  • Mediterranean diet
    • RCTs suggest that this diet may help with decline in cognition but not dementia (although benefit may be underestimated due to issues related to the study)
  • Cognitive interventions
    • There is data to support engaging in cognitively stimulating activities to improve cognition and reduce dementia
    • Commercial brain training tools have been promoted but not validated
  • Social engagement
    • Data suggests social engagement will delay onset of dementia but no evidence for prevention
    • Living alone, never married, divorced, or widowed have an increased risk of all-cause dementia
    • Dementia risk elevated for those with little social activity but data insufficient to confirm causation
  • Trials do not support the following interventions to prevent dementia:
    • NSAIDs
    • Rosiglitazone
    • Estrogen hormone therapy
    • Statins
    • Vitamins
    • Ginkgo biloba extract

CONCLUSION:

  • The Lancet Commission concludes that interventions for modifiable risk factors have the potential to delay or prevent a third of dementia cases
  • The authors suggest that while caution in interpreting PAF is advisable,

There is good evidence that treatment of hypertension reduces dementia incidence and preliminary evidence that modification of several risk factors has a beneficial effect on cognition. The interventions most likely to be beneficial (increasing education in early life, increasing physical activity and social engagement, reducing smoking, treating hypertension, diabetes, and hearing impairment) are safe and confer other health benefits.

Learn More – Primary Sources:

Commissions from the Lancet Journals: Dementia prevention, intervention, and care

Take a post-test and get CME credits

TAKE THE POST TEST

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Hormone Therapy Protect Against Alzheimer’s?
AUGS Statement on Anticholinergic Medications for Overactive Bladder and Dementia Risk
Does Fish Consumption Reduce Risk of Dementia?
Is Midlife Cardiovascular Fitness Associated with Reduced Risk for Dementia?
Omega-3 PUFAs: Do They Really Work for the Treatment of Dementia?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site